Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The placebo-controlled trial compared injections of cabotegravir given every eight weeks versus daily Truvada as PrEP.
Antiretrovirals likely drive up rates, both directly and by helping people live long enough to develop high blood pressure.
The agency has also lowered the weight threshold for film-coated tablets of the integrase inhibitor.
Researchers compared the demographics of participants in randomized controlled trials for antiretrovirals with the global HIV population.
This finding, which is in keeping with initial studies out of China and Italy, is preliminary as the CDC continues to gather data.
New forms of treatment and PrEP and, hopefully, an at least partially effective vaccine will be key to fighting the epidemic in the 2020s.
By altering the components of the vaccine regimen, researchers drove promising antibody and immune-cell responses.
Researchers gave the vaccine, previously studied in Thailand, to participants in South Africa.
Researchers analyzed the association between heavy drinking and immune function in those with untreated HIV.
The vaccine in the APPROACH study, which led to the Imbokodo and forthcoming Mosaico trails, prompted a robust immune response.
In fact, researchers report that since the first case was identified in 1999, HIV rates have surged.
“Rampant medical malpractices without any effective checks and balances are causing repeated outbreaks in Pakistan.”
Researchers broke down the various strategies that the gay men in the Opposites Attract study used to prevent HIV transmission.
Two gene-editing experts said Jiankui He’s actions were a “gross violation” of Chinese regulations and international standards.
Women in a global study began an HIV treatment regimen based on one of the two drugs after 20 weeks of gestation.
The study was conducted in Indonesia, Ukraine and Vietnam.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.